Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Retained Earnings (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Retained Earnings for 4 consecutive years, with $65000.0 as the latest value for Q4 2025.

  • For Q4 2025, Retained Earnings rose 100.01% year-over-year to $65000.0; the TTM value through Dec 2025 reached $65000.0, up 100.01%, while the annual FY2025 figure was $65000.0, 100.01% up from the prior year.
  • Retained Earnings was $65000.0 for Q4 2025 at Day One Biopharmaceuticals, down from $69000.0 in the prior quarter.
  • The five-year high for Retained Earnings was $69000.0 in Q3 2025, with the low at -$554.1 million in Q4 2024.
  • Historically, Retained Earnings has averaged -$168.9 million across 4 years, with a median of -$81500.0 in 2022.
  • The largest annual shift saw Retained Earnings surged 100.04% in 2023 before it plummeted 6976571.43% in 2024.
  • Over 4 years, Retained Earnings stood at -$71000.0 in 2022, then plummeted by 645794.37% to -$458.6 million in 2023, then dropped by 20.82% to -$554.1 million in 2024, then surged by 100.01% to $65000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $65000.0 in Q4 2025, $69000.0 in Q3 2025, and -$92000.0 in Q2 2025.